A new target for aggressive bladder cancer found

Share this content:

the ONA take:

A research team may have discovered a new avenue of attack in the battle against aggressive bladder cancer. Researchers based at the Institut Curie in France reviewed genetic data from the tumors of some 400 individuals with bladder cancer, with the aim of focusing on muscle-invasive bladder cancer, a particularly aggressive form of the cancer. They discovered that a portion of the bladder cancer cases, approximately 25%, demonstrated a hyperactive EGFR pathway. When the research team tested mice with this bladder cancer subgroup, they found that application of EGFR inhibitors was effective in slowing tumor growth. EGFR inhibitors are already used to treat breast cancer and lung cancer, and they may be able to help treat certain patients with bladder cancer as well. Although additional research is warranted, treatment with EGFR inhibitors, coupled with radiotherapy, could be a new, viable agent for combatting muscle-invasive bladder cancer.

Results of this study were published in the journal Science Translational Medicine.

A new target for aggressive bladder cancer found
A new target for aggressive bladder cancer found

News report: An international team of scientists have discovered a faulty process in certain bladder cancers that could point to new ways to treat patients with an aggressive form of the disease. "This interesting study builds on existing evidence suggesting that targeting EGFR may help treat ...

READ FULL ARTICLE From Cancerresearchuk
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs